
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
آخرین اخبار مالی و اقتصادی، تحولات بازار، گزارشها و تحلیلهای بازارهای مالی را در PipVero دنبال کنید.

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Mitsui & Co., Ltd. (MITSY) Q1 2027 Earnings Call Prepared Remarks Transcript

FAIRHAVEN, Mass.--(BUSINESS WIRE)--Acushnet Holdings Corp. (NYSE: GOLF) (“Acushnet”) published its second quarter 2026 financial results on August 6, 2026. The results are available via the Acushnet Investor Relations (http://www.acushnetholdingscorp.com/ir) and the U.S. Securities and Exchange Commission (https://www.sec.gov/cgi-bin/browse-edgar?company=acushnet&owner=exclude&action=getcompany) websites. Acushnet will hold a conference call for investors at 8:30 a.m. Eastern Time on Au.

PepsiCo is underperforming the consumer staples sector, hindered by weak North American volumes and slower growth versus Coca-Cola. I rate PEP a Hold, citing fair valuation, a 4.3% dividend yield, but a lack of near-term growth catalysts or innovation-driven inflection. International segments, especially IB Franchise and Asia Pacific Foods, remain bright spots with high-single digit organic growth, but domestic food volumes are a persistent drag.

Second quarter sales grew 5.8% to $917 million, driven by 4.3% organic sales growth and 1.5% favorable foreign exchange, with organic growth in both business segments Second quarter GAAP EPS of $0.70 compared to $0.57 in the prior year quarter Second quarter adjusted EPS grew 20% over the prior year to $0.96; exceeded adjusted EPS guidance of $0.89, primarily driven by better-than-expected organic volume growth Strong cash flow generation in the quarter supported $50 million of debt repayment; expect to repay a total of $100 to $150 million during the full year 2026 Increasing 2026 full year adjusted EPS guidance range to $3.10 to $3.25 from previous guidance of $2.93 to $3.17; updated full year adjusted EPS guidance range represents 10% to 15% growth over the prior year CLEVELAND, Aug. 6, 2026 /PRNewswire/ -- Avient Corporation (NYSE: AVNT), an innovator of materials solutions, today announced its second quarter results for 2026. Second quarter GAAP earnings per share (EPS) were $0.70 compared to $0.57 in the prior year quarter.

Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from averaging optimistic with pessimistic scenarios. Dupixent remains Sanofi's key growth driver, with a €25B 2030 sales target, but faces biosimilar risk post-2031 and a significant lawsuit threat. New pharma launches and pipeline assets are expected to offset legacy declines, targeting €10B in 2030 sales and with possible margin expansion toward 40%.

Quarterly profit jump fuelled largely by unknown US refund amount as Japanese video game giant records overall sales drop

Elon Musk lost roughly $87 billion in a single trading session on Wednesday, Aug.

Nvidia, Micron and AMD slipped in US pre-market trading on Thursday after SanDisk's outlook triggered a retreat across artificial-intelligence and memory-chip shares. At 5.30am ET, Nvidia was slightly lower, Micron had fallen 3.3% and AMD was down 1.9%, while SanDisk tumbled more than 9%.

Health insurer Oscar Health swung to a $361 million second quarter profit while eclipsing $1 billion in net income for the first six months of the year as health plan membership rose and medical costs eased.

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel Hunt and Stifel keeping buy ratings. The scale of the beat is the story.

Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb's U.S.-centric business, but at the cost of slower growth and integration risk. The reports had the industry thinking about a kind of dealmaking it has avoided for more than a decade.

Array Technologies, Inc. (ARRY) Q2 2026 Earnings Call Transcript

Chipotle delivered a Q2 beat with comp sales rebounding to 2.2% growth, driven by new menu items and a revamped rewards program. Despite revenue and comp growth, CMG's net income and EPS declined due to rising food and labor costs, compressing restaurant-level margins. I maintain a "Sell" rating, citing unsustainable valuation at over 20x P/E and ongoing EPS compression despite recent operational improvements.

A year ago, T-Rex 2x Long MSTR Daily Target ETF (CBOE:MSTU) traded at $74.90.